It is a combination of an angiotensin II receptor antagonist (AT1 subtype), Olmesartan Medoxomil, and a thiazide diuretic, hydrochlorothiazide (HCTZ). Olmesartan Medoxomil, a prodrug, is hydrolyzed to Olmesartan during absorption from the gastrointestinal tract.